Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.२१%
१,०९१.५१
-२.३०
-०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९१.५१——
SIXC
Communications
SIXC
Communications
SIXC
+०.२२%
६१०.११
+१.३४
+०.२२%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.३४%
१,२३७.९८
-१६.८३
-१.३४%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९३%
१,७४४.७१
-१६.४०
-०.९३%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४४.७१——
SIXM
Financials
SIXM
Financials
SIXM
-०.३७%
६४०.१८
-२.४०
-०.३७%
—६४२.५८६४४.८७६४८.४८६४०.१८——
SIXR
Staples
SIXR
Staples
SIXR
-०.१८%
८४९.५८
-१.५५
-०.१८%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२३%
२१७.४८
-०.५०
-०.२३%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.५२%
३,२६०.६९
+४८.८६
+१.५२%
—३,२११.८३३,२२७.२१३,२६८.३८३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६९%
९४२.४५
-६.५३
-०.६९%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.५२%
१,४६६.८०
-७.७२
-०.५२%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६६.८०——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२२%
२,३९७.५०
+५.३८
+०.२२%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥ ४,३२०.००
-१.२६%
(-५५.००) 1D
मे १, १५:३०:०० GMT+९  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
JP¥ ४,४००
High
JP¥ ४,४१०
Low
JP¥ ४,३१०
Mkt. cap
२.०१ खरब
Avg. vol.
७८.४२ हजार
Volume
१.६६ लाख
Dividend
२.६६%
Quarterly dividend
JP¥ २९
Ex dividend date
२०२६ मार्च ३०
P/E ratio
१२.८०
52-wk high
JP¥ ५,०४०
52-wk low
JP¥ ३,७५०
EPS
JP¥ ३३७
Shares outstanding
४.६७ करोड
No. of employees
२ हजार
News stories
From sources across the web
TipRanks
TipRanks
·
१७ घण्टा पहिले
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees१.७८ हजार
Founded१९४६ अगस्ट ९
HeadquartersMatsumoto, Nagano, जापान
Sector-
Websitekissei.co.jp
Last report
२०२६ जनवरी ३०
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
२६.८० अरब/ (२४.४१ अरब est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
२२.६६ अरब
२२.१९ अरब
२३.६४ अरब
२६.८० अरब
Cost of goods sold
११.७१ अरब
११.११ अरब
१२.०३ अरब
१४.५० अरब
Cost of revenue
११.७१ अरब
११.११ अरब
१२.०३ अरब
१४.५० अरब
Research and development expenses
१२.८९ अरब
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-६.७० अरब
८.९७ अरब
२०.५५ अरब
९.१५ अरब
Operating expense
९.४१ अरब
८.९७ अरब
२०.५५ अरब
९.१५ अरब
Total operating expenses
२१.१२ अरब
२०.०८ अरब
३२.५९ अरब
२३.६५ अरब
Operating income
१.५४ अरब
२.११ अरब
-८.९५ अरब
३.१६ अरब
Other non operating income
२.०० करोड
१.६० करोड
१०.०० लाख
१.०० करोड
EBT including unusual items
४.०४ अरब
५.७५ अरब
३.६६ अरब
४.२० अरब
EBT excluding unusual items
१.६३ अरब
२.८० अरब
-८.८२ अरब
३.५२ अरब
Income tax expense
९१.६० करोड
१.२३ अरब
३०.५० करोड
९१.५० करोड
Effective tax rate
२२.६९%
२१.३५%
८.३३%
२१.८१%
Other operating expenses
१२.९० करोड
-
-
-
Net income
३.१२ अरब
४.५२ अरब
३.२६ अरब
३.२३ अरब
Net profit margin
१३.७७%
२०.३६%
१३.८१%
१२.०५%
Earnings per share
-
-
-
-
Interest and investment income
१२.१० करोड
६९.२० करोड
२१.२० करोड
६१.४० करोड
Interest expense
-६०.०० लाख
-६०.०० लाख
-७०.०० लाख
-७०.०० लाख
Net interest expenses
११.५० करोड
६८.६० करोड
२०.५० करोड
६०.७० करोड
Depreciation and amortization charges
३.०९ अरब
-
-
-
EBITDA
२.६९ अरब
३.२६ अरब
-७.८२ अरब
४.३१ अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer